



SDI Review Form 1.6

Journal Name:	<u>International Journal of Medical and Pharmaceutical Case Reports</u>
Manuscript Number:	Ms_IJMPCR_28909
Title of the Manuscript:	Myocardial infarction in a young patient with chronic myeloid leukemia after nilotinib use.
Type of the Article	Case study

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<u>Compulsory</u> REVISION comments	I think these case reports are very important in the era of 2nd generation TKIs regarding their rare adverse events. I have one major question: Why did you start imatinib after the cardiac event of nilotinib? Because you have mentioned that the patient was resistant to imatinib therapy. So, why did you start dasatinib/bosutinib?	
<u>Minor</u> REVISION comments	Line 65: PDGFR). → PDGFR). Line 104: occuuring → occurring And please write all references in a uniform style. For example you used italics in some places.	
<u>Optional/General</u> comments		

As per the guideline of editorial office we have followed VANCOUVER reference style for our paper.

Kindly see the following link: <http://sciencedomain.org/archives/20>

Reviewer Details:

Name:	Burak Uz
Department, University & Country	Department of Internal Medicine, Division of Adult Hematology, Gazi University, Turkey